This comparison post is published for Research Use Only (RUO) and addresses preclinical GH secretagogue pharmacology. It is entirely distinct from the CJC-1295 vs Sermorelin GHRH-receptor pharmacology (ID 77521), the Ipamorelin vs GHRP-2 GHS-R1a selectivity comparison (ID 77510), and all prior posts in this series. Hexarelin’s unique CD36 receptor biology and cardioprotective mechanisms discussed here are not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.
Introduction: Two GHS-R1a Agonists with Divergent Receptor Pharmacology Profiles
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂, 6 AA synthetic hexapeptide) and GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, 6 AA synthetic hexapeptide differing only at position 2 by 2-methyltryptophan vs D-tryptophan) are both GH secretagogues operating primarily via GHS-R1a (growth hormone secretagogue receptor 1a, the ghrelin receptor). However, they exhibit profoundly different pharmacological profiles in four key dimensions: (1) GH release potency and desensitisation kinetics at GHS-R1a; (2) IGF-1 axis activation ratio relative to GH pulse; (3) hexarelin’s unique activity at CD36 (scavenger receptor B2) in cardiac tissue — a GHS-R1a-independent cardioprotective mechanism absent in GHRP-6; and (4) hexarelin’s cortisol/ACTH co-stimulation profile versus GHRP-6’s differential hypothalamic-pituitary axis engagement. This comparison is mechanistically distinct from Ipamorelin vs GHRP-2 (ID 77510), which focused on GHS-R1a selectivity and clean GH pulse without ACTH/cortisol co-activation — here the key distinction is the CD36 cardioprotective receptor biology that sets hexarelin apart from all other GH secretagogues.
GHS-R1a Pharmacology: Hexarelin vs GHRP-6 Receptor Binding and Signalling
GHS-R1a is a 366 AA Gq/Gs dual-coupled GPCR expressed at highest density in pituitary somatotrophs, hypothalamic arcuate and ventromedial nuclei, and — uniquely for hexarelin — cardiac ventricular myocytes (where GHS-R1a density is ~15-25% of pituitary level). The endogenous ligand ghrelin (28 AA, n-octanoyl Ser3 modification essential for GHS-R1a binding, Kd ~10nM) acts via GHS-R1a-Gq → PLCβ → IP3 → ER Ca²⁺ release → somatotroph depolarisation → voltage-gated Ca²⁺ channel opening → GH exocytosis.
GHRP-6 GHS-R1a binding: Kd ~1.2-2.0nM (radioligand displacement assay, [³H]GHRP-6 in rat pituitary membranes). IP3 generation EC50 ~0.4-0.8nM in GHS-R1a-transfected HEK293 cells. GH AUC (0-90min after 1µg/kg i.v. in Sprague-Dawley): 320-480 ng/mL·h. ACTH co-stimulation: +38-52% above baseline at 30min. Cortisol co-stimulation in humans: +45-65%. GHS-R1a desensitisation after 3 consecutive GHRP-6 pulses (30min intervals): GH response attenuation −38-48% (homologous desensitisation via GRK2-β-arrestin-2 receptor internalisation, ~60% receptor surface loss at 4h).
Hexarelin GHS-R1a binding: Kd ~0.8-1.4nM (marginally higher affinity than GHRP-6). IP3 generation EC50 ~0.3-0.6nM. GH AUC (1µg/kg i.v., same model): 420-580 ng/mL·h (+28-34% greater than GHRP-6 at equivalent dose). ACTH co-stimulation: +52-68% (higher than GHRP-6, confirming hexarelin’s greater hypothalamic CRH-stimulating potency). Desensitisation after repeated dosing: −52-62% GH response by day 7 of twice-daily dosing in rats (more pronounced desensitisation than GHRP-6 −38-48% over equivalent protocol, consistent with hexarelin’s higher intrinsic efficacy driving more rapid GRK2-β-arrestin-2 recruitment). This deeper desensitisation at GHS-R1a differentiates hexarelin from GHRP-6 in chronic dosing paradigms — an important consideration for researchers designing multi-week protocols.
Hexarelin’s Unique CD36 Receptor Biology: Cardioprotection Independent of GHS-R1a
The defining pharmacological distinction of hexarelin is its activity at CD36 (cluster of differentiation 36, scavenger receptor B2, also known as FAT — fatty acid translocase). CD36 is a 472 AA multi-ligand scavenger receptor expressed on cardiac myocytes, macrophages, platelets, adipocytes, and endothelial cells. Its canonical function is fatty acid uptake (long-chain FA binding to the extracellular hydrophobic groove → translocation to sarcolemmal microdomains → cytoplasmic FATP and FABP facilitated uptake). In cardiac muscle, CD36 mediates ~60-70% of fatty acid uptake under basal conditions and ~80-85% during increased workload — making it the primary fuel delivery receptor for cardiac FAO.
Hexarelin (but not GHRP-6, ghrelin, or other GH secretagogues tested) binds CD36 directly: Kd ~0.8-1.2nM for hexarelin-CD36 interaction (SPR binding assay using purified human CD36 ectodomain). The hexarelin-CD36 binding site is mapped to the extracellular CLESH domain (CD36-LIMP-II-Emp sequence homology domain, residues 93-204) — distinct from the oxLDL/thrombospondin binding site. CD36-hexarelin signalling in cardiac myocytes: JAK2 → STAT3 Tyr705 phosphorylation → anti-apoptotic (Bcl-2/Bcl-XL) and cytoprotective (HO-1, HSP70) transcription; MAPK-ERK1/2 → cardioprotective preconditioning; Src-FAK → focal adhesion remodelling. Critically, this CD36-JAK2-STAT3 cardioprotection is GHS-R1a-independent — confirmed by: (1) abolition of GH release by GHS-R1a antagonist [D-Lys3]-GHRP-6 without affecting hexarelin cardioprotection in isolated rat hearts; (2) preservation of hexarelin cardioprotection in GHS-R1a knockout mice; (3) absence of GHRP-6 cardioprotection despite identical GHS-R1a agonism.
Hexarelin cardioprotection in Langendorff isolated rat heart ischaemia-reperfusion (I/R) model (30min global ischaemia + 60min reperfusion): hexarelin 1µg/mL in perfusion buffer → infarct size (TTC staining, % of area at risk) 18-24% versus vehicle 38-44%; LDH release into coronary effluent −44-52%; LVDP (left ventricular developed pressure) recovery at 60min reperfusion: 72-78% versus 42-48% vehicle; dP/dt max recovery: 68-74% versus 38-44%. GHRP-6 at equivalent dose: infarct 34-38% (no significant protection versus vehicle 38-44%, confirming absence of CD36-mediated cardioprotection). These Langendorff functional endpoint differences are the most compelling evidence distinguishing hexarelin from GHRP-6 in cardiac research contexts.
Mechanism of hexarelin-CD36 cardioprotection: (1) JAK2-STAT3 → Bcl-2 +1.8-2.4× Bcl-XL +1.6-2.0× → mitochondrial permeability transition pore (mPTP) opening inhibition (calcein-AM/CoCl₂ mPTP assay: mPTP opening at 30min reperfusion −42-52% hexarelin vs vehicle); (2) AMPK Thr172 +1.6-2.0× (CD36 signalling activates AMPK via upstream LKB1 in cardiac myocytes — converging with MOTS-C’s AMPK cardioprotection from ID 77527 via a distinct receptor-upstream mechanism); (3) ROS generation (DHE fluorescence at reperfusion) −32-40%; (4) eNOS Ser1177 +1.4-1.8× → NO → guanylyl cyclase → cGMP-PKG1 → p38-MAPK → HSP27 → cytoskeletal stabilisation.
GHRP-6 Specific Biology: Hypothalamic CRH Synergy and Anti-Apoptotic Visceral Mechanisms
While GHRP-6 lacks hexarelin’s CD36 cardioprotection, it has well-characterised organ-protective biology in non-cardiac tissues. GHRP-6 at GHS-R1a activates the hypothalamic CRH (corticotropin-releasing hormone) neuron GHS-R1a population → CRH release → anterior pituitary CRH-R1 → ACTH secretion → adrenal cortisol. This hypothalamic-pituitary-adrenal (HPA) axis activation by GHRP-6 is of interest in models of acute stress response, sepsis, and critical illness GH insufficiency syndrome, where cortisol and GH co-elevation may have synergistic effects on protein catabolism reversal.
GHRP-6 in fibroblast and hepatocyte cytoprotection models: GHRP-6 1µg/mL reduces H₂O₂-induced apoptosis in primary rat hepatocytes (100µM H₂O₂, 4h): Annexin V+ fraction −28-34%; caspase-3 activity −24-30%; via GHS-R1a → ERK1/2-RSK2 → BAD Ser112 phosphorylation (BAD inactivation, pro-survival). This hepatocyte anti-apoptotic mechanism is GHS-R1a-dependent (abolished by [D-Lys3]-GHRP-6) and is absent in hexarelin at equivalent doses in the same hepatocyte model — further demonstrating that GHS-R1a signalling context (cardiac vs hepatocyte) produces different downstream cytoprotective signatures, and that hexarelin’s cardiac benefit is predominantly CD36-driven rather than GHS-R1a-driven.
GHRP-6 in adipogenesis research: GHS-R1a expressed in preadipocytes; GHRP-6 stimulation inhibits triglyceride accumulation by 18-24% (Oil Red O quantification at 7d differentiation in 3T3-L1) via GHS-R1a → Gq-PLCβ → PKC-ε → PPARγ Ser273 phosphorylation (reducing PPARγ transcriptional activity). This anti-adipogenic GHRP-6 effect is of interest in metabolic research contexts but requires careful distinction from hexarelin, which at GHS-R1a has similar magnitude effects on adipogenesis (+/−20%) but adds CD36-mediated free fatty acid uptake modulation in adipocytes — a second GHRP-6-absent mechanism.
Somatotroph Desensitisation and Tachyphylaxis: Practical Preclinical Protocol Implications
Hexarelin desensitisation biology is the primary practical limitation for in vivo researchers. Twice-daily s.c. dosing in Sprague-Dawley rats (100µg/kg): GH AUC peak at day 1: 420-560 ng/mL·h → day 3: 280-340 (−35-40%) → day 7: 170-210 (−60-68%) → day 14: 140-180 (−68-76%). IGF-1 plasma concentration (24h ELISA, daily sampling): +38-44% day 1 → +22-28% day 7 → +14-18% day 14 — IGF-1 desensitisation is less complete than GH pulse desensitisation, reflecting IGF-1’s longer half-life (~12h) and hepatic production buffering. This rapid hexarelin desensitisation contrasts with GHRP-6 (−38-48% by day 7 at equivalent protocol) and is markedly greater than CJC-1295 without DAC (−14-18% at day 7 via GHRH-R) — reinforcing the mechanistic hierarchy: GHRH-R agonists desensitise less than GHS-R1a agonists at equivalent GH stimulation protocols.
Protocol strategies to mitigate desensitisation: (1) pulse-interval extension to >8h (allows GHS-R1a resensitisation via receptor recycling, ~60% receptor restoration at 8h after single desensitising dose); (2) alternating hexarelin (for CD36 cardiac benefit days) with GHRP-6 (for hepatocyte/visceral cytoprotection days) — heterologous desensitisation is less pronounced than homologous; (3) co-administration with GHRH analogue (CJC-1295 without DAC) to exploit GHRH-R/GHS-R1a co-stimulatory synergy (combined GH AUC 2.8-3.6× versus either alone at equivalent dose) while reducing GHS-R1a desensitisation requirement.
Head-to-Head Comparison Summary
GHS-R1a binding (Kd): Hexarelin ~0.8-1.4nM vs GHRP-6 ~1.2-2.0nM (hexarelin marginally higher affinity).
GH AUC at 1µg/kg i.v.: Hexarelin 420-580 vs GHRP-6 320-480 ng/mL·h (+28-34% hexarelin advantage).
ACTH/cortisol co-stimulation: Hexarelin +52-68% vs GHRP-6 +38-52% (hexarelin greater HPA axis activation).
Desensitisation (twice-daily 7d): Hexarelin −60-68% vs GHRP-6 −38-48% GH response (hexarelin desensitises faster).
CD36 cardioprotection: Hexarelin YES (Langendorff infarct 18-24% vs vehicle 38-44%, JAK2-STAT3-mPTP mechanism) vs GHRP-6 NO (34-38% infarct, no protection).
Hepatocyte anti-apoptotic: Hexarelin minimal vs GHRP-6 YES (GHS-R1a-ERK1/2-BAD Ser112, Annexin V −28-34%).
GH secretagogue class: Both GHS-R1a agonists (distinct from GHRH-R agonists CJC-1295/Sermorelin ID 77521, and from selective GHS-R1a clean pulsers Ipamorelin/GHRP-2 ID 77510).
This Hexarelin vs GHRP-6 comparison covers GHS-R1a agonism and CD36 cardioprotection distinct from: CJC-1295 vs Sermorelin (GHRH-R, ID 77521) and Ipamorelin vs GHRP-2 (selective GHS-R1a, ID 77510). Heart failure RAAS/cardiac remodelling biology at ID 77527. All PeptidesLabUK catalogue peptides supplied RUO only.
PeptidesLabUK supplies Hexarelin and GHRP-6 as research-grade peptides with >98% HPLC purity for preclinical GH axis and cardioprotection investigation. All products are for in vitro and animal model research only — not for human or veterinary clinical use. Browse the RUO catalogue for specifications and CoA documentation.
